A Mini Review : Clinically Significant Potential Drug-Drug Interactions In COVID-19 and Comorbid Therapy
| Autor: | Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman, Oki Nugraha Putra |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Pharmaceutical Sciences and Research, Vol 7, Iss Special Issue on COVID-19, Pp 23-28 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2407-2354 2477-0612 |
| DOI: | 10.7454/psr.v7i4.1070 |
| Popis: | Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases. In administering COVID-19 therapy, we need to consider potential drug-drug interactions (pDDIs) with comorbid drugs. Most patients with comorbid diseases get polypharmacy, therefore the risk of pDDIs increases. Potential drug-drug interactions can cause unwanted effects such as toxicity to death. There is no on-label therapy for COVID-19 but FDA has Emergency Use Authorization (EUA) for hydroxychloroquine, chloroquine, azithromycin, remdesivir, ritonavir, and lopinavir. Some COVID-19 treatment potential drug-drug interactions have a level of severity C and D, so there is a high need for close monitoring during drug administration or modification therapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|